Grant: Master's Award: Canada Graduate Scholarships
McGill University
$27,000.00
CD109's Role in Fibroblast Regulation of Skin Fibrosis and Inflammation
EF 2024-25
Résumé
Scleroderma is a rare connective tissue disease marked by autoimmunity, inflammation, and fibrosis of the skin and internal organs. Affecting women four times more than men, its primary treatment—steroid therapy—has limited effectiveness. Fibrosis, caused mainly by Transforming Growth Factor Beta (TGF-B), and inflammation, regulated by the Nuclear Factor kappa B (NF-kB) pathway, are interrelated processes critical to scleroderma’s progression.
Our lab previously identified CD109 as a TGF-B co-receptor that inhibits TGF-B’s pro-fibrotic effects in human skin cells. Transgenic mice overexpressing CD109 in keratinocytes showed reduced fibrosis and inflammation. However, CD109’s role in dermal fibroblasts, which are essential for fibrosis development, remains unexamined. We hypothesize that CD109 downregulates fibrosis and inflammation in fibroblasts by modulating the NF-kB pathway.
Our objectives:
1) In vitro determination of CD109’s role in regulating
inflammatory and fibrotic signaling pathways in fibroblasts.
2) In vivo determination of CD109’s role in fibroblast regulation of skin fibrosis and
inflammation.
Using a fibroblast-specific CD109 knockout model, skin fibroblasts will be isolated and treated to induce fibrosis (TGF-B signaling) or inflammation (NF-kB signaling), with markers of inflammation and fibrosis analyzed. Knockout and wild-type mice will undergo similar treatments, and skin samples will be evaluated for the same markers.
We expect increased inflammatory and fibrotic signaling markers in the knockout mice, underscoring CD109’s regulatory role in these processes.
This research could provide insights into scleroderma’s mechanisms and lay the groundwork for targeting CD109 as a therapeutic approach for scleroderma and similar fibrotic diseases.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
529893
Name
Batal Adel
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
CD109's Role in Fibroblast Regulation of Skin Fibrosis and Inflammation
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cd109; Cre/Loxp Tissue-Specific Knockout; Extracellular Matrix Proteins; Immune Cells; Inflammation; Nf-Kb Signaling; Scleroderma; Signaling Crosstalk; Skin Fibrosis; Tgf-B Signaling
Abstract
Scleroderma is a rare connective tissue disease marked by autoimmunity, inflammation, and fibrosis of the skin and internal organs. Affecting women four times more than men, its primary treatment—steroid therapy—has limited effectiveness. Fibrosis, caused mainly by Transforming Growth Factor Beta (TGF-B), and inflammation, regulated by the Nuclear Factor kappa B (NF-kB) pathway, are interrelated processes critical to scleroderma’s progression.
Our lab previously identified CD109 as a TGF-B co-receptor that inhibits TGF-B’s pro-fibrotic effects in human skin cells. Transgenic mice overexpressing CD109 in keratinocytes showed reduced fibrosis and inflammation. However, CD109’s role in dermal fibroblasts, which are essential for fibrosis development, remains unexamined. We hypothesize that CD109 downregulates fibrosis and inflammation in fibroblasts by modulating the NF-kB pathway.
Our objectives:
1) In vitro determination of CD109’s role in regulating
inflammatory and fibrotic signaling pathways in fibroblasts.
2) In vivo determination of CD109’s role in fibroblast regulation of skin fibrosis and
inflammation.
Using a fibroblast-specific CD109 knockout model, skin fibroblasts will be isolated and treated to induce fibrosis (TGF-B signaling) or inflammation (NF-kB signaling), with markers of inflammation and fibrosis analyzed. Knockout and wild-type mice will undergo similar treatments, and skin samples will be evaluated for the same markers.
We expect increased inflammatory and fibrotic signaling markers in the knockout mice, underscoring CD109’s regulatory role in these processes.
This research could provide insights into scleroderma’s mechanisms and lay the groundwork for targeting CD109 as a therapeutic approach for scleroderma and similar fibrotic diseases.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Batal, Adel
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~